Trexquant Investment LP Raises Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Trexquant Investment LP boosted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 440.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,277 shares of the medical research company's stock after purchasing an additional 81,714 shares during the quarter. Trexquant Investment LP owned about 0.20% of Charles River Laboratories International worth $18,511,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Cerity Partners LLC lifted its position in Charles River Laboratories International by 65.9% during the third quarter. Cerity Partners LLC now owns 4,891 shares of the medical research company's stock worth $963,000 after acquiring an additional 1,943 shares during the last quarter. Glenmede Trust Co. NA boosted its stake in Charles River Laboratories International by 9.5% in the 3rd quarter. Glenmede Trust Co. NA now owns 1,210 shares of the medical research company's stock valued at $238,000 after purchasing an additional 105 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Charles River Laboratories International by 4.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,812 shares of the medical research company's stock valued at $1,933,000 after buying an additional 423 shares in the last quarter. Public Sector Pension Investment Board increased its position in Charles River Laboratories International by 15.1% during the 3rd quarter. Public Sector Pension Investment Board now owns 2,282 shares of the medical research company's stock worth $449,000 after buying an additional 300 shares during the period. Finally, Benjamin Edwards Inc. lifted its holdings in shares of Charles River Laboratories International by 256.5% during the third quarter. Benjamin Edwards Inc. now owns 1,451 shares of the medical research company's stock worth $286,000 after buying an additional 1,044 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Charles River Laboratories International Trading Down 2.9 %

Shares of CRL stock traded down $4.03 during mid-day trading on Friday, hitting $136.95. The company's stock had a trading volume of 1,666,195 shares, compared to its average volume of 771,482. The company has a market cap of $7.00 billion, a PE ratio of 912.99, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The company's fifty day simple moving average is $162.49 and its 200-day simple moving average is $180.77. Charles River Laboratories International, Inc. has a 52 week low of $132.99 and a 52 week high of $258.56.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.46 earnings per share. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Morgan Stanley decreased their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $190.00 to $170.00 in a report on Friday, March 21st. UBS Group restated a "neutral" rating and set a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Robert W. Baird lowered their price target on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Finally, Barclays lowered their target price on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company's stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $189.77.

Insider Activity

In related news, COO Birgit Girshick purchased 1,514 shares of the business's stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).